Quantum BioPharma Ltd.
QNTM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.01 | -0.01 | 0.02 |
| FCF Yield | -3.19% | -48.46% | -22.11% | -94.27% |
| EV / EBITDA | -6.60 | -0.79 | 0.26 | -0.24 |
| Quality | ||||
| ROIC | -112.55% | -58.48% | -55.40% | -26.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.36 | 0.20 | 0.49 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 54.12% | -408.27% | 75.85% | -470.64% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.27 | 0.97 | 0.71 |
| Interest Coverage | -20.60 | -9.72 | -379.75 | -403.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |